The sharp decline can be largely attributed to (1) one-time tail account ramp downs in retail, (2) furloughs, and (3) year-end volume discounts. Given the available margin levers and impending headwinds (e.g. wage hikes, etc.), we expect EBITDA margins to remain flat at ~11% in FY21 before Barring FY19 when overall revenue growth (including inorganic) came close to that of mid-cap peers (mostly organic), the stock always traded at a steep discount to the sector (in range of 8-10x one-year forward P/E). This was due to its inferior growth (organic revenue CAGR of 4% over FY15-20E v/s 12%+ for mid-cap peers), pay-out ratio (20% v/s average pay-out of 40%) and return profile (RoE of 18% v/s 30%+ for On our revised estimates, the stock is trading at an optically expensive multiple of ~17x FY21E EPS (depressed earnings though).